ATE445609T1 - Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen - Google Patents
Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungenInfo
- Publication number
- ATE445609T1 ATE445609T1 AT06720513T AT06720513T ATE445609T1 AT E445609 T1 ATE445609 T1 AT E445609T1 AT 06720513 T AT06720513 T AT 06720513T AT 06720513 T AT06720513 T AT 06720513T AT E445609 T1 ATE445609 T1 AT E445609T1
- Authority
- AT
- Austria
- Prior art keywords
- glucagone
- preparation
- receptor antagonists
- compounds
- therapeutic applications
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65249205P | 2005-02-11 | 2005-02-11 | |
| PCT/US2006/004461 WO2006086488A2 (en) | 2005-02-11 | 2006-02-09 | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE445609T1 true ATE445609T1 (de) | 2009-10-15 |
Family
ID=36694345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06720513T ATE445609T1 (de) | 2005-02-11 | 2006-02-09 | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8084489B2 (de) |
| EP (1) | EP1856090B1 (de) |
| JP (1) | JP4988604B2 (de) |
| KR (1) | KR20070104409A (de) |
| CN (1) | CN101115735B (de) |
| AT (1) | ATE445609T1 (de) |
| AU (1) | AU2006213894B2 (de) |
| BR (1) | BRPI0607015A2 (de) |
| CA (1) | CA2597073C (de) |
| CR (1) | CR9304A (de) |
| CY (1) | CY1109624T1 (de) |
| DE (1) | DE602006009773D1 (de) |
| DK (1) | DK1856090T3 (de) |
| EA (1) | EA200701705A1 (de) |
| ES (1) | ES2332470T3 (de) |
| IL (1) | IL184932A0 (de) |
| MA (1) | MA29432B1 (de) |
| MX (1) | MX2007009661A (de) |
| NO (1) | NO20074567L (de) |
| PL (1) | PL1856090T3 (de) |
| PT (1) | PT1856090E (de) |
| SI (1) | SI1856090T1 (de) |
| TN (1) | TNSN07313A1 (de) |
| WO (1) | WO2006086488A2 (de) |
| ZA (1) | ZA200706354B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013003B1 (ru) * | 2004-06-14 | 2010-02-26 | Эли Лилли Энд Компани | Антагонисты рецептора глюкагона, их получение и терапевтическое применение |
| PT2129654E (pt) | 2007-02-09 | 2014-09-04 | Metabasis Therapeutics Inc | Antagonistas do receptor de glucagina |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN104803891B (zh) | 2008-08-13 | 2017-10-20 | 症变治疗公司 | 胰高血糖素拮抗剂 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| CN103261165B (zh) | 2010-12-23 | 2015-08-26 | 辉瑞公司 | 胰高血糖素受体调节剂 |
| LT2673260T (lt) | 2011-02-08 | 2016-10-25 | Pfizer Inc. | Gliukagono receptoriaus moduliatorius |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN103732578B (zh) | 2011-07-22 | 2015-08-12 | 辉瑞大药厂 | 喹啉基胰高血糖素受体调节剂 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| EP3065736B1 (de) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung |
| EP3154956A4 (de) | 2014-06-12 | 2018-01-17 | Ligand Pharmaceuticals, Inc. | Glucagonantagonisten |
| WO2017049140A2 (en) | 2015-09-18 | 2017-03-23 | Wake Forest University Health Sciences | Angiotensin (1-7) analogs and methods relating thereto |
| EP3821917A1 (de) | 2015-10-05 | 2021-05-19 | Hettwer Holding ApS | Zusammensetzungen und verfahren zur behandlung von knochendefekten |
| CA2914601A1 (en) * | 2015-12-11 | 2017-06-11 | Wake Forest University Health Sciences | Angiotensin-(1-7) analogs and methods relating thereto |
| MA46089A (fr) | 2016-08-30 | 2019-07-10 | Regeneron Pharma | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
| EP3529278A1 (de) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Verfahren zur senkung des blutzuckerspiegels |
| MX2020002057A (es) | 2017-08-22 | 2020-07-13 | Regeneron Pharma | Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon. |
| EP3752249A1 (de) | 2018-02-13 | 2020-12-23 | Ligand Pharmaceuticals, Inc. | Glucagonrezeptorantagonisten |
| MX2022007665A (es) | 2019-12-20 | 2022-07-19 | Bayer Ag | Tiofenocarboxamidas sustituidas y sus derivados. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511683A (ja) * | 2001-12-03 | 2005-04-28 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
| AU2003233780A1 (en) * | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| ES2428538T3 (es) * | 2004-05-28 | 2013-11-08 | Eli Lilly And Company | Antagonistas del receptor de glucagón, preparación y usos terapéuticos |
| EA013003B1 (ru) * | 2004-06-14 | 2010-02-26 | Эли Лилли Энд Компани | Антагонисты рецептора глюкагона, их получение и терапевтическое применение |
-
2006
- 2006-02-09 WO PCT/US2006/004461 patent/WO2006086488A2/en not_active Ceased
- 2006-02-09 CN CN2006800046189A patent/CN101115735B/zh not_active Expired - Fee Related
- 2006-02-09 CA CA2597073A patent/CA2597073C/en not_active Expired - Fee Related
- 2006-02-09 AT AT06720513T patent/ATE445609T1/de active
- 2006-02-09 PL PL06720513T patent/PL1856090T3/pl unknown
- 2006-02-09 PT PT06720513T patent/PT1856090E/pt unknown
- 2006-02-09 US US11/815,987 patent/US8084489B2/en not_active Expired - Fee Related
- 2006-02-09 DE DE602006009773T patent/DE602006009773D1/de active Active
- 2006-02-09 ES ES06720513T patent/ES2332470T3/es active Active
- 2006-02-09 KR KR1020077018437A patent/KR20070104409A/ko not_active Ceased
- 2006-02-09 AU AU2006213894A patent/AU2006213894B2/en not_active Ceased
- 2006-02-09 EP EP06720513A patent/EP1856090B1/de active Active
- 2006-02-09 SI SI200630534T patent/SI1856090T1/sl unknown
- 2006-02-09 BR BRPI0607015-9A patent/BRPI0607015A2/pt not_active IP Right Cessation
- 2006-02-09 JP JP2007555195A patent/JP4988604B2/ja not_active Expired - Fee Related
- 2006-02-09 DK DK06720513T patent/DK1856090T3/da active
- 2006-02-09 EA EA200701705A patent/EA200701705A1/ru unknown
- 2006-02-09 MX MX2007009661A patent/MX2007009661A/es active IP Right Grant
-
2007
- 2007-07-30 IL IL184932A patent/IL184932A0/en unknown
- 2007-07-31 ZA ZA200706354A patent/ZA200706354B/xx unknown
- 2007-08-10 TN TNP2007000313A patent/TNSN07313A1/en unknown
- 2007-08-10 CR CR9304A patent/CR9304A/es not_active Application Discontinuation
- 2007-09-10 NO NO20074567A patent/NO20074567L/no not_active Application Discontinuation
- 2007-09-11 MA MA30221A patent/MA29432B1/fr unknown
-
2009
- 2009-11-12 CY CY20091101192T patent/CY1109624T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1856090E (pt) | 2009-11-18 |
| CA2597073C (en) | 2014-11-25 |
| CY1109624T1 (el) | 2014-08-13 |
| EP1856090B1 (de) | 2009-10-14 |
| TNSN07313A1 (en) | 2008-12-31 |
| AU2006213894B2 (en) | 2011-12-08 |
| NO20074567L (no) | 2007-11-08 |
| MA29432B1 (fr) | 2008-05-02 |
| JP4988604B2 (ja) | 2012-08-01 |
| EA200701705A1 (ru) | 2008-02-28 |
| KR20070104409A (ko) | 2007-10-25 |
| ZA200706354B (en) | 2008-11-26 |
| CN101115735B (zh) | 2013-01-09 |
| CN101115735A (zh) | 2008-01-30 |
| CA2597073A1 (en) | 2006-08-17 |
| MX2007009661A (es) | 2007-09-25 |
| US20100137417A1 (en) | 2010-06-03 |
| JP2008530102A (ja) | 2008-08-07 |
| WO2006086488A3 (en) | 2006-12-14 |
| AU2006213894A1 (en) | 2006-08-17 |
| EP1856090A2 (de) | 2007-11-21 |
| IL184932A0 (en) | 2007-12-03 |
| SI1856090T1 (sl) | 2010-02-26 |
| US8084489B2 (en) | 2011-12-27 |
| CR9304A (es) | 2008-03-31 |
| BRPI0607015A2 (pt) | 2009-12-01 |
| ES2332470T3 (es) | 2010-02-05 |
| WO2006086488A2 (en) | 2006-08-17 |
| DE602006009773D1 (de) | 2009-11-26 |
| DK1856090T3 (da) | 2009-11-30 |
| PL1856090T3 (pl) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| WO2007106181A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| WO2007120270A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1856090 Country of ref document: EP |